Kornimate/medical-research-clean huggingface dataset:
magnesium chloride versus placebo in patients who have had a stroke

Conditions: Stroke

Summary: the purpose of this study is to evaluate the effect of six intravenous (iv) infusions of magnesium chloride versus placebo in patients who have residual muscle weakness from a stroke that occurred three months to four years ago.

the hypothesis being tested is that these six treatments will improve muscle weakness and lead to an improvement in functioning/activities of daily living as measured by the 100-point barthel index, three months after their last treatment versus their baseline measure, and that the mean difference between the treatment and placebo groups of patients will be at least three points in this index.

Eligibility criteria:
inclusion criteria: 1. subjects of either sex above 18 years of age 2. documented history of stroke 3 months to four years ago 3. subjects may have had two or more strokes 4. must have residual muscle weakness with a 25% or greater difference in strength between the right and left sides of the body 5. must be assessed as a 2 or 3 on the modified rankin scale 6. must have a barthel score at or below 85 exclusion criteria: 1. any traumatic brain injury or other brain injury apart from stroke 2. renal insufficiency or renal failure 3. any medical or physical condition that would interfere with the measurements to be conducted 4. any physical therapy in a facility outside their home within three days of screening

Keywords: a stroke that occurred three months to four years ago
the use of prophylactic antibiotics in isolated blowout fractures

Conditions: Orbital Fractures; Orbital Cellulitis

Summary: the purpose of the research is to perform a quality assurance evaluation using randomized prospective analysis the rate of orbital cellulitis as a complication of nonsurgical orbital blowout fracture in patients treated versus not treated with prophylactic antibiotics. the investigators goal is to show the use of prophylactic antibiotics in orbital blowout fractures does not significantly decrease the rate of orbital cellulitis and is thus not indicated.

orbital fractures are a common occurrence in association with a wide variety of blunt trauma injuries to the face. one type of fracture is that involving the orbital floor, or an isolated blowout fracture. one common current practice is to use prophylactic antibiotics in these cases to prevent the theoretical occurrence of an orbital cellulitis originating from sinus flora, though there is no current standard of care regarding this practice. many surgeons may elect to not use antibiotics for this very reason. the use of prophylactic antibiotics in isolated blowout fractures where there is no occlusion of the ostium is not defined, and no prospective controlled study has been undertaken to suggest the most appropriate course of action to take. our goal in this study is to determine a correct course of action for these patients.

Eligibility criteria:
inclusion criteria: * isolated orbital blow out fracture in patients between the ages 5 to 99 years old exclusion criteria: * involvement of the orbital rim in the floor fracture requiring the use of antibiotics * involvement of the orbital rim in the floor fracture * radiographic evidence of occlusion of the maxillary sinus ostium * determined need for surgical intervention or prior use of synthetic implanted material in or around the involved maxillary sinus * any symptoms of sinonasal disease in the preceding 3 month for any reason * any use of oral or iv antibiotics in the preceding 3 month for any reason * documented allergy to penicillin or amoxicillin prohibiting its use * any currently immunosuppressed state, including actively treated autoimmune disease; use of steroids, immunomodulatory medication, or chemotherapy within the last year; diagnosis of active cancer within the last year
vestibular testing: consistency and effects over time

Conditions: Dizziness

Summary: the goal of this study is to test the consistency and repeatability of a portable goggle system for testing optokinetic, ocular, and reaction time. the study examines the day to day consistency, time of day and learning effects as well as any secondary motion sickness.

the goal of this study was to test the constancy and repeatability of this test by testing it in different individuals and different times of day, after a variety of tasks and after repeated performance

Eligibility criteria:
inclusion criteria: * age 18 to 65 * both females and males * staff and students at all levels at the university of miami or first-degree - relatives/significant others of those individuals. exclusion criteria: * history of vestibular disorder/dysfunction * central processing disorder * impaired vision without corrective lenses (max 20/60 uncorrected) * moderate to severe hearing loss \[\>55 decibel (db) pure tone average (pta), \<50% word identification\]
degradation of the glycocalyx in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: this study will provide novel information to the literature base for the pathophysiology of aneurysmal subarachnoid hemorrhage. the association of breakdown products in the serum of asah patients were reported in a very small case series of 3 patients, as mentioned above. however, while their results are intriguing and encouraging, our study will provide more definitive information about the gc in asah. if there is a positive correlation, the results of this study will guide future investigations into new therapies for this devastating disease such as mmp inhibition with doxycycline.

1. the study will aim to recruit all eligible patients at utmck and the university of virginia hospital over a 12 month period. our main outcome measure is degradation of the glycocalyx in patients with asah. all eligible patients with confirmed asah admitted to the neuro-intensive care unit will be enrolled after consent is obtained from the family and/or the patient. serum samples will be drawn from each patient on admission (day 1) and every other day until day 13 for a total of 7 samples per patient. the following serum tests will be performed: 2. measurement of serum syndecan-1 by elisa 3. measurement of serum heparan-sulfate by elisa 4. measurement of serum matrix metalloproteinases -9 5. measurement of serum matrix-metalloproteinase-1 6. measurement of urinary microalbumin-to-creatinine ratio 7. measurement of daily tcds (all patients currently receive daily tcds as part of the asah protocol at utmck and uva hospital) 8. outcomes: a) chart review: i) incidence of dci as defined by a consensus committee on this subject and published in the journal stroke \[29\]. ii) in-hospital mortality will be recorded b) follow-up performed by phone call or searching the social security death index \[30\]: i) 30-day mortality ii) 90-day mortality c) outcomes follow-up: i) the glasgow outcome scale 12 weeks post asah \[31\]

Eligibility criteria:
inclusion criteria: * • age 18 years of age and older * cerebral aneurysm on ct-angio exclusion criteria: * • comfort care only orders, * the absence of an aneurysm on ct-angiography, * onset of aneurysm rupture \> 24 hours, * and inability to obtain informed consent from patient or family pregnant women
study evaluating interferon and cci-779 in advanced renal cell carcinoma

Conditions: Carcinoma, Renal Cell; Kidney Neoplasms

Summary: the primary objective of this study is efficacy. the primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with cci-779 \[temsirolimus\], administered intravenously \[iv\] once weekly and the combination of cci-779, administered iv once weekly with interferon alfa \[ifn alfa\] subcutaneously \[sc\] three times per week \[tiw\], compared with the overall survival of subjects treated with ifn alfa (sc tiw) alone, in poor-prognosis subjects with advanced rcc.


Eligibility criteria:
inclusion criteria: * this study will be conducted in subjects with histologically confirmed, advanced (stage iv or recurrent disease) rcc who have not received prior systemic therapy for their disease, exclusion criteria: * subjects with central nervous system (cns) metastases * prior anticancer therapy for rcc * prior investigational therapy/agents within 4 weeks of randomization

Keywords: advanced renal cell carcinoma kidney cancer
study evaluating multiple ascending dose in schizophrenia patients

Conditions: Healthy

Summary: this is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of slv-313 sr tablets administered orally to subjects with schizophrenia and schizoaffective disorder.


Eligibility criteria:
inclusion criteria: * men, aged 18-50 years old * women, aged 18-50 years old exclusion criteria: * non-lactating women, aged 18-50 years old * non-pregnant women, aged 18-50 years old

Keywords: safety tolerability schizophrenia
post marketing surveillance and special surveillance for mirapex® tablet in patients with idiopathic parkinson's disease

Conditions: Parkinson Disease

Summary: the objectives of this study are to investigate issues or questions about mirapex tablets as shown below through the post marketing surveillance (pms) study upon approval. * unexpected adverse events (especially, serious adverse events (saes)) * to find out the status of incidence of adverse events under actual practice * factors on the safety profile * factors on the efficacy profile


Eligibility criteria:
inclusion criteria: * among the patients with idiopathic parkinson's disease, from those receiving mirapex tablets first after a contract of the study to the requested number of cases will be consecutively enrolled without skipping exclusion criteria: * following patients are contraindicated. 1. patients who are hypersensitive to mirapex or its ingredients 2. refer to the insert paper for other contraindication. * following patients should be carefully administered. 1. patient with renal impairment 2. refer to the insert paper for other precaution.
early rhbnp on myocardial work in patients with stemi

Conditions: ST-Segment Elevated Myocardial Infarction

Summary: the study intends to evaluate the efficacy of early rhbnp on myocardial work in patients with anterior st-segment elevation myocardial infarction after percutaneous coronary intervention


Eligibility criteria:
inclusion criteria: * 1. anterior myocardial infarct (anterior myocardial infarct is defined as persistent chest pain for 30 mins at least, with st-segment elevation of at least 0.2 mv in two or more contiguous precordial leads) within 12 hours after onsets of symptom; 2. no contraindication for rhbnp; 3. left anterior descending (lad) as culprit vessel, with timi 0-1 grade. exclusion criteria: * 1.cardiogenic shock (systolic bp \<90mmhg after fluid infusion or systolic bp\<100mmhg after vasoactive drugs); 2. history of myocardial infarct; 3.severe arrhythmia: with iii degree a-v block ,atrial fibrillation,ventricular fibrillation,ventricular tachycardia; 4. any history of severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension or active hepatitis); neutropenia or thrombocytopenia; known acute pancreatitis; 5. pregnant or lactating; 6. life expectancy≤12 months; 7. inability to follow the protocol and comply with follow-up requirements or any other reason the investigator feels would place the patient at increased risk;

Keywords: st-segment elevated myocardial infarction rhbnp non-invasive myocardial work
toward an automated method of abdominal fat segmentation of mr images

Conditions: Obesity

Summary: subjects will undergo a brief magnetic resonance (mri) scan. the resulting images will be used to compare two abdominal fat segmentation techniques. the first technique is already validated and in use. the second technique was recently developed and has not been validated. the hypothesis is that the second technique will be the faster and more reliable of the two.


Eligibility criteria:
inclusion criteria: * ambulatory * cognitively sound exclusion criteria: * body mass index less than 18 or greater than 45 kilograms per square meter

Keywords: obesity
iressa vs placebo as maintenance therapy in locally advanced nsclc

Conditions: Non Small Cell Lung Carcinoma

Summary: the aim of the study if to determine if iressa can prolong the period of time without any disease worsening (time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy


Eligibility criteria:
inclusion criteria: * histologically confirmed non small cell lung cancer. * locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy). * chemotherapy with regimens containing cisplatin or carboplatin is mandatory * response to combined therapy exclusion criteria: * no previous treatment with zd1839 or any other egfr-targeted therapy * no progressive disease after combined therapy for locally advanced nsclc * no presence of metastatic disease * no other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * any unresolved chronic toxicity from previous anticancer therapy.

Keywords: locally advanced non small cell lung cancer (stage iiia and iiib)
study to evaluate the safety, pk, and dose response of paltusotine in subjects with carcinoid syndrome

Conditions: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas

Summary: the purpose of this study is to evaluate the safety, pharmacokinetics (pk), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. this study consists of a randomized treatment phase followed by an open-label extension (ole) phase.


Eligibility criteria:
inclusion criteria: 1. male or female subjects ≥18 years of age. 2. documented carcinoid syndrome requiring medical therapy. 1. not currently treated with somatostatin receptor ligands agonists for at least 12 weeks prior to screening and actively symptomatic. this can include treatment-naïve subjects. 2. subjects currently treated with lanreotide, octreotide long acting release, or short acting octreotide (subcutaneous or oral) who are currently symptomatically controlled 3. evaluable documentation of locally advanced or metastatic histopathologically confirmed well-differentiated neuroendocrine tumor (net). 4. no significant disease progression as assessed by the investigator within the last 6 months before initiation of study drug dosing. exclusion criteria: 1. diarrhea attributed to any condition(s) other than carcinoid syndrome. 2. uncontrolled/severe diarrhea associated with significant volume contraction, dehydration, or hypotension. 3. requires second line treatments (eg, telotristat) for control of carcinoid syndrome symptoms. 4. treatment with specific net tumor therapy \<4 weeks before screening (such as everolimus or sunitinib) or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy (prrt), and/or tumor debulking \<12 weeks before screening. 5. history of another primary malignancy \<3 years prior to the date of first dose, except for adequately treated basal or squamous cell carcinoma of the skin, cancer of the breast or cervix in situ, previously treated or concurrent malignancy determined to be clinically stable and not requiring treatment. 6. diabetes mellitus treated with insulin for less than 6 weeks prior to the study entry

Keywords: neuroendocrine tumor paltusotine crn00808 carcinoid syndrome lanreotide octreotide somatostatin agonist
observational study to assess a 6-months treatment with gladem

Conditions: Depressive Disorder

Summary: * evaluation of a 6-months treatment with gladem * experiences with the internet for performing a postmarketing study (pms) trial


Eligibility criteria:
inclusion criteria: * men and women at least 18 years old * de novo prescription of gladem * treatment with gladem intended for at least 6 months * depressive disorders exclusion criteria: * known hypersensitivity against sertraline * concomitant treatment with monoamine oxidase (mao)-inhibitors, selegiline, moclobemide (washout for at least 14 days necessary) * concomitant treatment with other serotoninergic substances like tryptophan or fenfluramine * instable epilepsy according to product information (october 1998) gladem prescription was possible with precautions in the following cases: * patients with stable epilepsy * patients with restricted liver functions * suicidal patients * patients in emotional state and marked sleeping disorders according to product information (october 1998) gladem should only be prescribed during pregnancy and lactation period, if the expected benefit was greater than the risk. women of childbearing age should use gladem only in combination with sufficient contraception.
high versus low dose of magnesium sulfate as initial tocolytic agent for preterm labour in symptomatic placenta previa.

Conditions: Placenta Previa Bleeding

Summary: to assess the efficacy and safety of alternative magnesium sulfate regimens when used as single agent tocolytic therapy for prevention of preterm labour in patients with symptomatic placenta previa and subsequent changes in the cervical length .

placenta previa is implantation of placenta on or near internal os .it is classified into major degree when lower edge of placenta lies within 2 cm from internal os , and minor degree if lower edge of placenta at lower uterine segment but more than 2 cm from internal os . there are many risk factors for developing placenta previa including multi parity , multiple pregnancy , increased maternal age (\>35y ) , previous uterine surgery , history of placenta previa (4-8%) . a significant degree of uterine contractility has been observed with symptomatic placenta previa. it is directly associated with vaginal bleeding. however, a large percentage of women who have placenta previa associated with haemorrhage will experience subclinical uterine contractions before the onset of overt vaginal bleeding. therefore, the use of tocolytic agents in management of placenta previa seems reasonable . magnesium sulfate alters calcium up take, binding and distribution in smooth muscles of the uterus, so reduces the frequency of cell depolarization and inhibits myometrial contraction . in addition to its tocolytic action magnesium sulfate also provide neuroprotection to preterm infant . . at women health hospital, assiut university, egypt our policy is using magnesium sulfate as first line for tocolysis for placenta previa patients with preterm uterine contractions. by giving a loading dose of 4 g on 150 ml saline intravenous infusion over 20 minutes, and a maintenance dose of 6g/6h on 500 ml saline slow intra venous infusion

Eligibility criteria:
inclusion criteria: 1. singleton pregnancy. 2. gestational age between 28 weeks to 37 weeks. 3. patients presented to the hospital with per vaginal bleeding and in whom a clinical diagnosis of placenta previa is confirmed by trans vaginal ultrasound. 4. placenta previa with preterm uterine contractions (\< 3 contractions in 10 minutes) 5. ability to provide informed consent. exclusion criteria: 1. placental abruption . 2. women with placenta previa and severe attack of bleeding need immediate termination 3. clinical criteria of intra uterine infection. 4. intrauterine growth restriction . 5. fetal anomalies. 6. fetal distress. 7. intrauterine fetal death. 8. preterm rupture of membrane 9. high order multiple pregnancies. 10. treatment with any tocolytic agent before maternal transport. 11. inability or refusal to provide informed consent. 12. women with any contraindication for use of magnesium sulfate as patients with renal failure. 13. patients with bleeding disorder or on anticoagulant therapy .
a universal eye drop adherence monitor to measure and improve adherence to ocular medications

Conditions: Medication Adherence; Glaucoma

Summary: glaucoma is the second leading cause of visual impairment worldwide. eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective. however, adherence to eye drop treatment is poor with only 50% of patients regularly taking their prescribed eye drops. the investigators are developing the devers drop device (d3) eye drop monitor to accurately measure eye drop cap removal and to improve eye drop-taking behavior. the investigators will test eye drop adherence with the d3 device in a randomized, prospective clinical trial.

universal adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutions. the devers drop device (d3) will accurately track when a patient removes an eye drop bottle cap, communicate usage data wirelessly to a database that researchers can access, and send alerts to patients when a medication is due. in addition to helping patients maintain their dosing schedule, the d3 will also provide adherence information to researchers and eye care providers, which will help to understand poor treatment outcomes and to develop improved treatment strategies.the clinical benefits of the device in improving adherence will initially be assessed and targeted towards glaucoma, but the ability of the device to be attached to all fda-approved eye drop bottle caps will make this device attractive to all patients that need consistent daily use of eye drops. randomized, prospective clinical trial: the investigators will enroll 50 participants (25 male, 25 female) into a prospective trial with duration of up to 50 days. the inclusion criteria are those who are prescribed latanoprost eye drop to be used once per day at bedtime, and own a functioning android or apple iphone smartphone (ios) with bluetooth and cellular connectivity. the investigators will exclude patients who currently use smartphone medication reminders and those with severe cognitive impairment limiting their ability to understand a questionnaire. the 50-day period is useful for glaucoma studies because patients revert to their normal dosing pattern within two weeks after their last visit. this study will include two stages: stage 1) a 25-day period evaluating baseline patient adherence with the d3 device; and stage 2) a subsequent 25-day period to determine the effect of no reminder versus daily reminder using the d3 app, which includes integrated audio and visual reminders.

Eligibility criteria:
inclusion criteria: * patients who are prescribed latanoprost eye drop to be used once per day at bedtime, and own a functioning smartphone and have a password-protected home wireless connection. exclusion criteria: * patients who currently use smartphone medication reminders and those with severe cognitive impairment limiting their ability to understand a questionnaire.

Keywords: adherence medication glaucoma device
dislocated unstable distal both-bone forearm fractures in children

Conditions: Fracture; Forearm; Distal; Child; Treatment

Summary: we create a follow-up study of kirschner wire fixation of a unstable dislocated distal both-bone forearm fracture.

children who arrive at the emergency unit with a dislocated both-bone distal forearm fracture will be asked to join the trial. after an unstable reposition, the fracture will be fixated with 2 kirschner-wires. the arm will be immobilised in above elbow cast during 4 weeks. outpatient clinic visits till a follow-up of 6 months. during these visits we will investigate: consolidation and dislocation on x-ray, function of both arms, complains in daily living and complications.

Eligibility criteria:
inclusion criteria: * both-bone forearm fracture * distal * dislocated * unstable after reposition * age \< 16 years exclusion criteria: * fracture older than 1 week * no informed consent * refracture * open fracture (gustillo 2 and 3) * both fractures of type torus

Keywords: fracture forearm distal child treatment